BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 26163633)

  • 21. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
    Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
    Boveri E; Passamonti F; Rumi E; Pietra D; Elena C; Arcaini L; Pascutto C; Castello A; Cazzola M; Magrini U; Lazzarino M
    Br J Haematol; 2008 Jan; 140(2):162-8. PubMed ID: 18028479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study.
    England JT; Szuber N; Sirhan S; Dunne T; Cerquozzi S; Hill M; Villeneuve PJA; Ho JM; Sadikovic B; Bhai P; Krishnan N; Dowhanik S; Hillis C; Capo-Chichi JM; Tsui H; Cheung V; Gauthier K; Sibai H; Davidson MB; Bankar A; Kotchetkov R; Gupta V; Maze D
    Leukemia; 2024 Mar; 38(3):570-578. PubMed ID: 38321107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype.
    Beleva EA
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.
    Moliterno AR; Williams DM; Rogers O; Isaacs MA; Spivak JL
    Exp Hematol; 2008 Nov; 36(11):1480-6. PubMed ID: 18723264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group.
    Gill H; Leung GMK; Ooi MGM; Teo WZY; Wong CL; Choi CW; Wong GC; Lao Z; Rojnuckarin P; Castillo MRID; Xiao Z; Hou HA; Kuo MC; Shih LY; Gan GG; Lin CC; Chng WJ; Kwong YL
    Clin Exp Med; 2023 Dec; 23(8):4199-4217. PubMed ID: 37747591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of CHIP-Related Mutation and Risk of Cardio-Cerebrovasculars Events in Patients with Myeloproliferative Neoplasms].
    Han X; Bai BB; Feng CC; Zhao S; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):190-196. PubMed ID: 38387920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms.
    Wang X; LeBlanc A; Gruenstein S; Xu M; Mascarenhas J; Panzera B; Wisch N; Parker C; Goldberg JD; Prchal J; Hoffman R; Najfeld V
    Exp Hematol; 2009 Oct; 37(10):1194-200. PubMed ID: 19615425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic basis and molecular profiling in myeloproliferative neoplasms.
    Luque Paz D; Kralovics R; Skoda RC
    Blood; 2023 Apr; 141(16):1909-1921. PubMed ID: 36347013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [JAK2 V617F mutation burden and its clinical implications in 415 patients with myeloproliferative neoplasm].
    Liu Y; Liu C; He N; Wang M; Zhang X; Tang D; Ji C; Ma D
    Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):191-5. PubMed ID: 25854460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.
    Nischal S; Bhattacharyya S; Christopeit M; Yu Y; Zhou L; Bhagat TD; Sohal D; Will B; Mo Y; Suzuki M; Pardanani A; McDevitt M; Maciejewski JP; Melnick AM; Greally JM; Steidl U; Moliterno A; Verma A
    Cancer Res; 2013 Feb; 73(3):1076-85. PubMed ID: 23066032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stem cell defects in Philadelphia chromosome negative chronic myeloproliferative disorders: a phenotypic and molecular puzzle?
    Bock O; Hussein K; Kreipe H
    Curr Stem Cell Res Ther; 2007 Sep; 2(3):253-63. PubMed ID: 18220909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience.
    Popova-Labachevska M; Cvetanoski M; Ridova N; Trajkova S; Stojanovska-Jakimovska S; Mojsovska T; Stojanoski Z; Pivkova-Veljanovska A; Panovska-Stavridis I
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2023 Dec; 44(3):57-62. PubMed ID: 38109450
    [No Abstract]   [Full Text] [Related]  

  • 37. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.
    Carobbio A; Finazzi G; Antonioli E; Guglielmelli P; Vannucchi AM; Dellacasa CM; Salmoiraghi S; Delaini F; Rambaldi A; Barbui T
    Exp Hematol; 2009 Sep; 37(9):1016-21. PubMed ID: 19559071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
    Tefferi A; Vannucchi AM; Barbui T
    Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
    Helbig G
    Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis of risk factors for thromboembolism in patients with JAK2
    Zhang YH; Teng GS; Ma JY; Hu X; Du CX; Wang Y; Hu NB; Li YQ; Shao ZH; Bai J
    Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3652-3657. PubMed ID: 38018064
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.